🔎 Trials Near Me

Avaleht › Dermatomüosiit › Massachusetts

Dermatomüosiit kliinilised uuringud osariigis Massachusetts

5 uuringut haiguse Dermatomüosiit jaoks otsivad osalejaid osariigis Massachusetts.

Linnad osariigis Massachusetts

Ametlik uuringutekst (inglise keeles)

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  • Research Site, Boston
VärbamineFaas 3
Vanused 18–75 · Kõik sood · Uuendatud 24. sept 2026 · NCT06455449

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 23. sept 2026 · NCT03816345

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

  • Boston Children's Hospital - Accepting Young Adults and Juvenile Patients, Boston
VärbamineFaas 2/3
Vanused 6–75 · Kõik sood · Uuendatud 17. sept 2026 · NCT06154252

A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]

  • Brigham and Women's Hospital, Boston
  • CTC - Brigham & Women's Hospital, Boston
  • CTH - Brigham & Women's Hospital, Boston
VärbamineFaas 3
Vanused 18 ja vanemad · Kõik sood · Uuendatud 15. sept 2026 · NCT05895786

A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

  • Brigham And Womens Hospital, Boston
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 14. juuli 2026 · NCT07115745

Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.